ARTICLE | Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

November 14, 2018 1:00 PM UTC

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly identify effective treatments for newly diagnosed and recurrent glioblastoma. Dosing will begin early next year.

GBM AGILE will evaluate multiple agents across biomarker-defined subgroups, seamlessly moving compounds that clear the Phase II efficacy threshold into Phase III within the same protocol. GCAR President Brian Alexander told BioCentury the trial is "designed to be a long-standing mechanism to test an innumerable number" of therapies (see "Patient-Powered Precision")...

BCIQ Company Profiles

Bayer AG